

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC: Ltd., Karnik Road, Chikan Ghar,  
Kalyan, Dist. Thane - 421 301.

Corporate Office: Empire House, 3rd Floor, 214, Dr. D.N. Road, Fort, Mumbai - 400 001.

Tel No.: 022-22078382 | CIN No.: L99999MH1942PPLC003556 | PAN No.: AAACC2056K  
Website : www.thechemopharmalaboratoriesltd.com | Email ID : chemopharmalab@gmail.com

January 27, 2025

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services  
25<sup>th</sup> Floor, P. J. Towers,  
Dalal Street, Mumbai-400001  
Script Id: 506365

Subject: Outcome of Board Meeting Held on Monday, January 27, 2025

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. January 27, 2025, approved the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2024 along with the Limited Review Report thereon.

1. We are enclosing herewith, a copy of the Un-Audited Financial Results for the quarter and nine months ended December 31, 2024 along with the Limited Review Report thereon by auditor for the quarter and nine months ended December 31, 2024.
2. Approved the Appointment of S K JAIN & Co. Membership No. 1473 and COP No. 3076 Practicing Company Secretary as the Secretarial Auditor of the Company for the Financial Year 2024-25.

The Meeting commenced at 04.00 p.m. and concluded at 04.50 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI  
DIRECTOR  
(DIN -03063364)



# Sanjay Rane & Associates LLP

CHARTERED ACCOUNTANTS

Phone : +91 (22) 4919 8585  
Email : admin@ssrane.net  
Website : www.ssraneandco.com  
LLP IN : ABZ-0863

## LIMITED REVIEW REPORT

To,

Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of CHEMO PHARMA LABORATORIES LIMITED for the quarter ended December 31, 2024 and year to date results for the nine months period from April 01, 2024 to December 31, 2024 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates LLP

Chartered Accountants

Firm Reg. No. 121089W/W100878



CA. Abhijeet Deshmukh

Partner

Membership No. 129145

Date: January 16, 2025

Place: Mumbai

UDIN: 25129145BMIWMC9362



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421 301.

Corporate Office: Empire House, 3rd Floor, 214, Dr. D.N. Road, Fort, Mumbai - 400 001.

Tel No.: 022-22078382 | CIN No.: L99999MH1942PPLC003556 | PAN No.: AAACC2056K  
Website : www.thechemopharmalaboratoriesltd.com | Email ID : chemopharmalab@gmail.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND MONTHS ENDED 31ST DECEMBER 2024

(Rs. In Thousand)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31st Dec., 2024	30th Sept 2024	31st Dec., 2023	31st Dec., 2024	31st Dec., 2023	31st March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations			-			
II	Other Income	(1,488)	6,310	7,023	7,839	15,915	18,382
III	<b>Total Revenue (I + II)</b>	<b>(1,488)</b>	<b>6,310</b>	<b>7,023</b>	<b>7,839</b>	<b>15,915</b>	<b>18,382</b>
IV	<b>Expenses</b>						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	54	54	54	177	131	185
	(5) Depreciation and Amortisation Expenses	14	14	21	41	62	83
	(6) Administrative and Other Expenses	192	142	183	803	801	1,679
	(7) Finance Costs	-	-	-	-	-	-
	<b>Total Expenses</b>	<b>260</b>	<b>209</b>	<b>258</b>	<b>1,021</b>	<b>994</b>	<b>1,946</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,765</b>	<b>6,818</b>	<b>14,922</b>	<b>16,436</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,765</b>	<b>6,818</b>	<b>14,922</b>	<b>16,436</b>
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,765</b>	<b>6,818</b>	<b>14,922</b>	<b>16,436</b>
X	<b>Tax Expenses</b>						
	(1) Current Tax	-	-	4	-	4	1,662
	(2) Tax Adjustment Previous Year	-	-	-	-	-	4
	(3) Deferred Tax	-	-	-	-	-	1,688
	(4) MAT Credit Entitlement	-	-	-	-	-	1,078
XI	<b>Profit/(Loss) for the period from continuing operations (IX - X)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,761</b>	<b>6,818</b>	<b>14,918</b>	<b>12,004</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	<b>Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,761</b>	<b>6,818</b>	<b>14,918</b>	<b>12,004</b>
XVI	<b>Other Comprehensive Income</b>						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>(1,748)</b>	<b>6,100</b>	<b>6,761</b>	<b>6,818</b>	<b>14,918</b>	<b>12,004</b>
XVIII	<b>Earnings per Share :</b>						
	(1) Basic	(1.17)	4.07	4.51	4.55	9.95	8.00
	(2) Diluted						

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2024 have been reviewed by the Audit Committee in their Meeting held on 27.01.2025 and approved by the Board of Directors of its Meeting held on 27.01.2025. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.



for Chemo Pharma Laboratories Limited

*Ashok Somani*

Ashok Somani

Director

DIN: 03063364

Date : 27th January, 2025  
Place : Mumbai

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. -Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421 301.

Corporate Office: Empire House, 3rd Floor, 214, Dr. D.N. Road, Fort, Mumbai - 400 001.

Tel No.: 022-22078382 | CIN No.: L99999MH1942PPLC003556 | PAN No.: AAACC2056K  
Website : www.thechemopharmalaboratoriesltd.com | Email ID : chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2024

(Rs. In Thousand)

PARICULARS	UNAUDITED QUARTER ENDED			UNAUDITED NINE MONTHS ENDED		AUDITED YEAR ENDED
	31.12.2024	30.09.24	31.12.2023	31.12.2024	31.12.2023	31.03.2024
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	1210	2,358	1,304	4533	3,660	16436
Benefit / (Charge):	-	-	-			
Impact of Deferred Income (Government Grant) Amortized to Income						
Impact of Fair Valuation of Financial Instruments	-2958	3,742	5,457	2285	11,258	1666
Impact of Actuarial Gain / Loss Taken OCI						
Impact of Adjustment of Deferred Tax						1078
Net Profit / (Loss) for the Period (as per AS)	-1748	6,100	6,761	6818	14,918	12,004

Date: 27th January, 2025  
Place: Mumbai



for Chemo Pharma Laboratories Limited

A handwritten signature in black ink, appearing to read 'Ashok Somani', written over a horizontal line.

Ashok Somani  
Director

DIN: 03063364

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar,  
Kalyan, Dist. Thane - 421 301.

Corporate Office: Empire House, 3rd Floor, 214, Dr. D.N. Road, Fort, Mumbai - 400 001.

Tel No.: 022-22078382 | CIN No.: L99999MH1942PPLC003556 | PAN No.: AAACC2056K  
Website : www.thechemopharmalaboratoriesltd.com | Email ID : chemopharmalab@gmail.com

- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – Not Applicable
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – Not Applicable, No default
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – Not Applicable
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI  
DIRECTOR  
(DIN -03063364)

